S
Stefan Faderl
Researcher at University of Texas MD Anderson Cancer Center
Publications - 586
Citations - 36426
Stefan Faderl is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 96, co-authored 577 publications receiving 34155 citations. Previous affiliations of Stefan Faderl include Penn State Milton S. Hershey Medical Center & Hackensack University Medical Center.
Papers
More filters
Journal ArticleDOI
Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy.
Marylou Cardenas-Turanzas,Farhad Ravandi-Kashani,Jorge E. Cortes,Elias Jabbour,Stefan Faderl,Sherry Pierce,Hagop M. Kantarjian +6 more
TL;DR: Baseline expectations of serious AEs at the end of life of patients with AML undergoing ST were established and the AE profiles of new investigational interventions or therapies could be compared with what would be expected in such circumstances from the combined effect of disease progression, expected complications of the AML therapy, and therapies delivered in previous historical contexts.
Journal ArticleDOI
Factors associated with outcome of secondary MDS and AML: Review of 2,182 patients at MDACC.
Francesco Paolo Tambaro,William G. Wierda,Guillermo Garcia-Manero,Jorge E. Cortes,Sherry Pierce,Mario Annunziata,Mimmo Ripaldi,Gautam Borthakur,Elias Jabbour,Farhad Ravandi,Stefan Faderl,Hagop M. Kantarjian +11 more
TL;DR: Type of prior malignancy and prior treatment associated with AML and MDS will be presented, and prior hematological neoplasms were most common.
Journal Article
Value of interphase fluorescent in situ hybridization (iFISH) studies in monitoring response to STI571 therapy in patients with Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia (CML)
Hagop M. Kantarjian,Susan O'Brien,Kimberly Hayes,Armand B. Classman,Stefan Faderl,Deborah A. Thomas,Mary Beth Rios,Renaud Capdeville,Moshe Talpaz +8 more
Journal ArticleDOI
Biological and Clinical Features of Trisomy 21 Acute Myeloid Leukemia
Paolo Strati,Hagop M. Kantarjian,Jorge E. Cortes,Farhad Ravandi,Naveen Pemmaraju,Guillermo Garcia-Manero,Tapan M. Kadia,Elias Jabbour,Aziz Nazha,Gautam Borthakur,Stefan Faderl,Alfonso Quintás-Cardama,Naval Daver +12 more
TL;DR: PKC412+AZA is safe and well tolerated at the intended doses with good ORR in high risk pts with R/R AML and MDS, with no difference between the 2 groups.
Book ChapterDOI
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
TL;DR: Optimal use of multi-targeted therapeutic strategies, including monoclonal antibody therapy, in the treatment schema for de novo Ph-positive ALL will be paramount in ensuring success in the eradication of this disease.